Front Cover. To overcome the limitations of Pt(II) drugs for cancer treatment (intrinsic or acquired resistance, severe side‐effects), the investigations on Pt(IV) complexes and their anticancer activity provide a promising strategy. Beside higher kinetic inertness and lower toxicity compared to Pt(II), Pt(IV) complexes are armed with two axial ligands for further modification of their pharmacological properties. Three Pt(IV) complexes with biologically active lipoate ligands were presented by W. Weigand et al. in their research article at 10.1002/cbdv.202200695. Due to the low solubility of the Pt(IV) complex with two lipoate ligands (2), the Pt(IV) complexes 1 and 3 containing one lipoate ligand were analyzed for their biological properties.